Resmedica Sp. z o.o.

The trials here

What the 18 trials at this site are about, from their registry records.

Conditions

• Multiple sclerosis17 trials
• Myasthenia gravis1 trial

Phase

• Phase 312 trials
• Phase 25 trials
• Phase 41 trial

Status

• Active, not recruiting9 trials
• Recruiting4 trials
• Completed3 trials
• Not yet recruiting2 trials

Lead sponsor

• Hoffmann-La Roche3 trials
• Novartis Pharmaceuticals3 trials
• TG Therapeutics, Inc.3 trials
• Sanofi2 trials
• Amgen1 trial
• and 6 more

Running trials

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)

  NCT07673744· Phase 2· TG Therapeutics, Inc.· Source

• Active, not recruiting

  Study of an On-Body Injection System for Home Use of Ocrelizumab in People with Multiple Sclerosis

  2025-523726-40-00· Phase 3· F. Hoffmann-La Roche AG· Source

• Recruiting

  A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)

  NCT07503873· Phase 2· TG Therapeutics, Inc.· Source

• Recruiting

  A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

  NCT07282574· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

  NCT07325292· Phase 3· Sanofi· Source

• Recruiting

  A Randomized, Double-blind, Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics and Clinical Effects between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis

  2024-512914-16-00· Phase 3· Amgen Inc.· Source

• Active, not recruiting

  Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

  NCT06700343· Phase 3· Amgen· Source

• Active, not recruiting

  A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients with Relapsing-remitting Multiple Sclerosis.

  2022-501622-37-00· Phase 3· Celltrion Inc.· Source

• Active, not recruiting

  Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

  NCT06141473· Phase 3· Sanofi· Source

• Recruiting

  Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

  NCT05877963· Phase 3· TG Therapeutics, Inc.· Source

• Recruiting

  Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis

  NCT05054140· Phase 2· Immunic AG· Source

• Active, not recruiting

  Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

  NCT05147220· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

  NCT04586023· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

  NCT04035005· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS

  2023-507906-15-00· Phase 3· Novartis Pharma AG· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple sclerosis5 recruiting
• Myasthenia gravis1 recruiting

Closed trials

• Active, not recruiting

  Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis

  NCT06444113· Phase 4· Novartis Pharmaceuticals· Source

• Completed

  A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

  NCT05798520· Phase 2· Biogen· Source

• Completed

  An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

  NCT04353492· Phase 3· Novartis Pharmaceuticals· Source